import requestsfrom bs4 import BeautifulSoup# Send a request to the Finviz homepageurl = "https://finviz.com"headers = {'User-Agent': 'Mozilla/5.0'} # A user-agent helps avoid being blockedresponse = requests.get(url, headers=headers)soup = BeautifulSoup(response.content, "html.parser")# Find all the home page tablestables = soup.find_all("table", {"class": "t-home-table"})# Iterate through the tables and rows to find the Top Gainersfor table in tables: for tr in table.find_all("tr"): td = tr.find_all("td") row = [i.text for i in td] # Check if the row contains the 'Top Gainers' signal if len(row) > 5 and row[5] == 'Top Gainers': print(row)

**Big picture: Armata Pharmaceuticals (ARMP) is today’s clear stand-out, rocketing +103 % on blockbuster Phase 2a trial data, but the move sits atop a very speculative, loss-making biotech—handle with care.** 🚀 --- ### What jumped today? Below are the U.S.-listed stocks that gained >7 % on Oct-22 **and** traded >1 M shares. After tightening the screen to price > $5, volume > 5 M, and move > 20 %, only one name makes the cut: ```reference [{"type":"table-json","id":2}] ``` | Ticker | Company | Price ($) | Move (%) | Volume | |--------|---------|-----------|----------|--------| | ARMP.A | Armata Pharmaceuticals | 6.81 | 103.17 | 13.1 M | *(Source: Ainvest FinScreener, 22-Oct-2025)* --- ### Why did ARMP double? • **Positive Phase 2a data:** Armata’s bacteriophage therapy (AP-SA02) produced an 88 % response rate in a Staph aureus bloodstream-infection trial, vastly outperforming placebo. • **Bullish sell-side take:** H.C. Wainwright reiterated a Buy rating and a $9 target, implying a further ~28 % upside from yesterday’s close. • **Retail frenzy:** Social platforms lit up, adding momentum to the rally. --- ### Caveats to keep on your radar 1. **Zero revenue, negative EPS:** Armata still has no commercial product and reported a TTM EPS of –$1.03. 2. **High volatility:** A 55 %+ historical volatility and 2.97 beta signal sharp swings in either direction. 3. **Dilution risk:** Management may tap equity markets to fund the planned Phase 3 trial, which could pressure the share price. 4. **Binary outcomes:** Future gains hinge on successful Phase 3 data and regulatory approvals—outcomes are uncertain. --- ### How to think about it • **Trading angle:** If you’re a short-term trader, watch for profit-taking and potential secondary offerings. Tight risk controls are essential given the post-rally pullback in after-hours trading. • **Long-term investors:** Assess whether the bacteriophage platform provides durable competitive advantage and consider Armata’s cash runway (currently limited) versus impending trial costs. Diversification across better-capitalised biotechs may reduce single-name risk. • **Sector read-through:** The outsized move underscores how clinical catalysts can dominate biotech returns—use this as a reminder to size positions appropriately and balance them with steadier holdings. --- ### Quick notes on **TD** & **Lennar (LEN)** Your Finviz scrape flagged Toronto-Dominion (TD) and Lennar (LEN) among “Top Gainers.” Both rallied ~2-3 % yesterday, likely on broader financials/real-estate strength, but their moves were modest compared with ARMP. Happy to dive deeper if those interest you. --- 🤔 **Your turn:** Given your focus on fast-moving tech/biotech names, are you looking to **trade around catalysts** like Armata’s trial data, or do you prefer **longer holding periods** targeting fundamentals? Your time horizon will guide the best next steps.